Pasar al contenido principal

FARMACOS INNOVADORES PARA ENFERMEDADES NEURODEGENERATIVAS (ALZHEIMER Y ESCLEROSIS LATERAL AMIOTROFICA) ACTIVOS EN DIANAS NEUROGENICAS Y NEUROPROTECTORAS

SAF2015-64948-C2-1-R

•
Nombre agencia financiadora Ministerio de Economía y Competitividad
Acrónimo agencia financiadora MINECO
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2015
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Unidad de gestión Dirección General de Investigación Científica y Técnica
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)
Identificador persistente http://dx.doi.org/10.13039/501100003329

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

New cinnamic – N-benzylpiperidine and cinnamic – N,N-dibenzyl(N-methyl)amine hybrids as Alzheimer-directed multitarget drugs with antioxidant, cholinergic, neuroprotective and neurogenic properties

  • Estrada, Martín
  • Herrera-Arozamena, Clara
  • Pérez, Concepción
  • Viña, Dolores
  • Romero Jódar, Alejandro
  • Morales-García, José A.
  • Pérez Castillo, Ana
  • Rodríguez-Franco, María Isabel
Here we describe new families of multi-target directed ligands obtained by linking antioxidant cinnamic-related structures with N-benzylpiperidine (NBP) or N,N-dibenzyl(N-methyl)amine (DBMA) fragments. Resulting hybrids, in addition to their antioxidant and neuroprotective properties against mitochondrial oxidative stress, are active at relevant molecular targets in Alzheimer’s disease, such as cholinesterases (hAChE and hBuChE) and monoamine oxidases (hMAO-A and hMAO-B). Hybrids derived from umbellic – NBP (8), caffeic – NBP (9), and ferulic – DBMA (12) displayed balanced biological profiles, with IC50s in the low-micromolar and submicromolar range for hChEs and hMAOs, and an antioxidant potency comparable to vitamin E. Moreover, the caffeic – NBP hybrid 9 is able to improve the differentiation of adult SGZ-derived neural stem cells into a neuronal phenotype in vitro., Financial support from the Spanish Ministry of Economy and Competitiveness (MINECO, grants SAF2012-31035 and SAF2015-64948-C2-1-R to MIRF; grant SAF2014-52940-R to APC) partially financed by FEDER funds, and Consejo Superior de Investigaciones Científicas (CSIC, grant PIE-201580E109) is gratefully acknowledged. ME thanks COLCIENCIAS (Colombia) for a Ph.D. fellowship., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

New neurogenic lipoic-based hybrids as innovative Alzheimer's drugs with σ-1 agonism and β-secretase inhibition

  • Estrada, Martín
  • Pérez, Concepción
  • Soriano, Elena
  • Pricl, Sabrina
  • Morales-García, José A.
  • Pérez Castillo, Ana
  • Rodríguez-Franco, María Isabel
et al., [Background]: Neurogenic agents emerge as innovative drugs for the treatment of Alzheimer's disease (AD), whose pathological complexity suggests strengthening research in the multi-target directed ligands strategy. [Results]: By combining the lipoic acid structure with N-benzylpiperidine or N,N-dibenzyl(N-methyl)amine fragments, new multi-target directed ligands were obtained that act at three relevant targets in AD: σ-1 receptor (σR), β-secretase-1 (BACE1) and acetylcholinesterase (AChE). Moreover, they show potent neurogenic properties, good antioxidant capacity and favorable CNS permeability. Molecular modeling studies on AChE, σR and BACE1 highlight relevant drug-protein interactions that may contribute to the development of new disease-modifying drugs. [Conclusion]: New lipoic-based σ agonists endowed with neurogenic, antioxidant, cholinergic and amyloid β-peptide-reducing properties have been discovered for the potential treatment of AD., Financial support from the Spanish Ministry of Economy and Competitiveness (MINECO, grants SAF2012-31035 and SAF2015-64948 to MIRF; grants SAF2010-16365 and SAF2014-52940-R to APC), Fundación de Investigación Médica Mutua Madrileña Automovilística (grant AP103952012 to MIRF), and Consejo Superior de Investigaciones Científicas (CSIC, grant PIE-201580E109 to MIRF) is gratefully acknowledged. ME thanks COLCIENCIAS (Colombia) for a Ph.D. fellowship. ES, and EL and SP thank CESGA (Santiago de Compostela, Spain) and CINECA (Bologna, Italy – Project SIMBIOSY) supercomputer centres, respectively, for providing access to computational resources., Peer Reviewed